Announcement • Jul 15
Burcon NutraScience Corporation, Annual General Meeting, Sep 16, 2026 Burcon NutraScience Corporation, Annual General Meeting, Sep 16, 2026. Announcement • Jun 16
Burcon NutraScience Corporation Achieves New Production Record And Reports Growth In Sales Of Peazzaz, FavaPro And Puratein Protein Ingredients Burcon NutraScience Corporation announced continued commercial and operational momentum, highlighted by strong growth in sales compared to the previous quarter and the establishment of a new production record with its manufacturing partner, marking another milestone in Burcon's transition from technology development to commercial-scale ingredient sales. Approximately 50% growth in sales compared to the previous quarter, combined with record production performance, reflects the continued transition of Burcon from technology development to commercial-scale ingredient sales. Commercial demand continues to expand across Burcon's portfolio of pea, fava and canola protein ingredients, with customer activity ranging from product development and formulation support through commercial production and repeat purchase. The Company's April & May sales increased significantly, indicating calendar Second Quarter on track for 50% growth compared to the prior quarter. Burcon's protein ingredients are currently being utilized across a diverse range of applications, including ready-to-mix beverages, powdered nutrition products, nutrition bars, snacks, baked goods and plant-based foods. Demand across the Company's Peazzaz, FavaPro and Puratein protein product portfolio reflects the broad commercial applicability of Burcon's protein technologies and growing market demand for high-performance plant-based protein ingredients that deliver nutrition, functionality and taste. Burcon achieved a new production record with Re ProMan LLC, its manufacturing partner, exceeding its calendar First Quarter daily average by approximately 60% over the past couple weeks. The achievement reflects continued improvements in manufacturing efficiency, production throughput and process optimization, further strengthening the Company's ability to support growing customer demand. Announcement • Jun 13
Burcon NutraScience Corporation to Report Fiscal Year 2026 Results on Jun 24, 2026 Burcon NutraScience Corporation announced that they will report fiscal year 2026 results on Jun 24, 2026 Announcement • Apr 27
Burcon NutraScience Corporation announced that it has received CAD 6.9 million in funding from RE ProMan LLC On April 27, 2026, Burcon NutraScience Corporation closed the transaction. The company announced that it has issued convertible debentures for gross proceeds of CAD 2,900,000 in final tranche. An insider of the Company subscribed for Convertible Debentures totaling approximately CAD 1,700,000 in principal amount under the final tranche. In total, insiders of the Company subscribed for Convertible Debentures totaling approximately CAD 4,400,000 in principal amount in aggregate under the Private Placement. Announcement • Jan 28
Burcon NutraScience Corporation to Report Q3, 2026 Results on Feb 11, 2026 Burcon NutraScience Corporation announced that they will report Q3, 2026 results on Feb 11, 2026 Announcement • Nov 13
Burcon NutraScience Corporation announced that it expects to receive CAD 4 million in funding Burcon NutraScience Corporation announced a non-brokered private placement to issue 4,000 convertible debentures at an issue price of CAD 1,000 per debenture for an aggregate principal amount of up to CAD 4,000,000 on November 12, 2025. Insiders of the Company have committed to participating at a minimum of CAD 2,000,000 in principal amount. The Offering is subject to the approval of the Toronto Stock Exchange ("TSX"). Each Convertible Debenture will consist of CAD 1,000 principal amount, bear interest at a rate of 15% per annum, payable in full upon maturity, and be unsecured. The principal amount outstanding under the Convertible Debentures and all accrued and unpaid interest thereon will be payable in cash 48 months from the date of issuance of the Convertible Debentures. The Convertible Debentures will be convertible at the option of the holder, in whole or in part, into common shares of the Corporation (the "Shares") at a conversion price of CAD 2.27 per Share (the "Conversion Price"). The Convertible Debentures and the Shares issuable upon conversion of the Convertible Debentures will be subject to a four month and one day statutory resale restriction pursuant to applicable Canadian securities laws. The Offering is expected to close on or about November 28, 2025 and is subject to execution of subscription agreements by the placees and to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the TSX. Announcement • Nov 06
Burcon NutraScience Corporation to Report Q2, 2026 Results on Nov 12, 2025 Burcon NutraScience Corporation announced that they will report Q2, 2026 results on Nov 12, 2025 Announcement • Jul 30
Burcon NutraScience Corporation to Report Q1, 2026 Results on Aug 13, 2025 Burcon NutraScience Corporation announced that they will report Q1, 2026 results on Aug 13, 2025 Announcement • Jul 09
Burcon NutraScience Corporation, Annual General Meeting, Sep 17, 2025 Burcon NutraScience Corporation, Annual General Meeting, Sep 17, 2025. Location: british columbia, vancouver Canada Announcement • Jul 02
Burcon NutraScience Corporation Unveils Cafe Latte Plant-Based Protein Beverage Concept Burcon NutraScience Corporation announced to unveil a Cafe Latte plant-based protein beverage concept at the upcoming Institute of Food Technologists Annual Meeting and Exposition ("IFT FIRST") in Chicago, IL, from July 13-16 in exhibit booth S4066. Cold Cafe Latte beverage containing plant proteins photo. The 2025 IFT FIRST food, beverage, foodservice, nutrition and nutraceuticals tradeshow will be held in Chicago July 13-16 and next-generation plant proteins will be front and center. Plant protein innovator Burcon NutraScience (Booth S4066) will feature its range of 90%+ pure pea, sunflower, canola, hemp and fava plant-based proteins with all featuring neutral flavor and aroma, and smooth mouthfeel. During the show, Burcon will be sampling a tasty cold Cafe Latte beverage containing 10 grams of high-purity pea and sunflower seed plant protein in a standard serving. IFT FIRST attendees will have the opportunity to sample the rich, coffee-inspired beverage made with Burcon's proprietary blend of Peazazz®?C pea protein and Solatein™? sunflower protein. The Cafe Latte contains 10 grams of plant protein in an eight-ounce serving showcasing the clean taste, smooth texture, and superior functionality of Burcon's high-purity protein ingredients-delivering an exceptional sensory. experience. In addition to the Cafe Latte, Burcon will exhibit its full portfolio of innovative plant-based proteins, each offering 90%+ protein purity, neutral flavor, and excellent performance for food, beverage, food service, nutritional, and nutraceutical applications. Featured Burcon protein ingredients on display at IFT FIRST include: Peazazz®? C - 90%+ pea protein. Puratein®? C - 90% + canola protein. Solatein™? - 90%+ sunflower protein and a sunflower protein concentrate. HPI95 - 90%+ hempseed protein. FavaPro™? - 90%+ fava protein. Announcement • Jun 27
Burcon NutraScience Corporation Auditor Raises 'Going Concern' Doubt Burcon NutraScience Corporation filed its Annual on Jun 25, 2025 for the period ending Mar 31, 2025. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern. Announcement • Jun 17
Burcon NutraScience Corporation to Report Fiscal Year 2025 Results on Jun 25, 2025 Burcon NutraScience Corporation announced that they will report fiscal year 2025 results on Jun 25, 2025 Announcement • Mar 11
Burcon NutraScience Corporation (TSX:BU) completed the acquisition of Protein Production Facility. Burcon NutraScience Corporation (TSX:BU) entered into a binding agreement to acquire Protein Production Facility on January 31, 2025. The closing of the transaction is subject to certain conditions, including satisfactory due diligence and approval by the parties.
Burcon NutraScience Corporation (TSX:BU) completed the acquisition of Protein Production Facility on March 10, 2025. Announcement • Feb 13
Burcon NutraScience Corporation has completed a Follow-on Equity Offering in the amount of CAD 9.433821 million. Burcon NutraScience Corporation has completed a Follow-on Equity Offering in the amount of CAD 9.433821 million.
Security Name: Common Shares
Security Type: Common Stock
Securities Offered: 110,986,126
Price\Range: CAD 0.085
Transaction Features: Rights Offering Announcement • Jan 09
Burcon Nutrascience Corporation Announces Launch of Solatein Sunflower Protein Is Now Available for Sampling Burcon NutraScience Corporation announced the launch of SolateinTM sunflower protein isolate, a groundbreaking high-purity protein ingredient designed to meet the evolving preferences of consumers worldwide. An emerging sector of consumers prioritizing protein intake is creating new opportunities for protein supplement products. According to Goldman Sachs Research, the number of GLP-1 weight management medication users is expected to increase rapidly over the next five years. These users are actively seeking protein to support their nutrition needs2. Burcon anticipates that its expanded portfolio of highly differentiated plant-based protein solutions is well-positioned to meet this significant demand. Burcon's SolateinTM sunflower protein is expected to redefine the standards for high-purity protein ingredients. It boasts a neutral flavor, off-white color and exceptional functionality, providing ease of formulation in a variety of food applications, in particular, those with delicate flavors. With over 90% protein purity, SolateinTM is a non-GMO, hypoallergenic protein that surpasses the performance of protein ingredients on the market today. It is rich in sulfur-containing amino acids, which enhances nutritional profiles and complements existing formulations. Burcon's innovative process upcycles by- products from sunflower seed oil production into a highly pure food ingredient, offering a sustainable protein solution. Announcement • Nov 22
Burcon NutraScience Corporation has filed a Follow-on Equity Offering in the amount of CAD 8.671788 million. Burcon NutraScience Corporation has filed a Follow-on Equity Offering in the amount of CAD 8.671788 million.
Security Name: Common Share
Security Type: Common Stock
Securities Offered: 142,628,096
Price\Range: CAD 0.0608
Transaction Features: Rights Offering Announcement • Oct 30
Burcon NutraScience Corporation to Report Q2, 2025 Results on Nov 13, 2024 Burcon NutraScience Corporation announced that they will report Q2, 2025 results on Nov 13, 2024 Announcement • Oct 09
Burcon NutraScience Corporation Launches Puratein® Canola Protein Burcon NutraScience Corporation announced the launch of its Puratein® canola protein into the rapidly growing, multi-billion-dollar egg replacement market. Burcon's canola protein is well-suited for use in baked goods, offering food manufacturers a sustainable and cost- effective alternative to eggs. Egg prices have surged due to supply challenges, with demand outpacing production in the U.S. Over the past two years, avian influenza outbreaks have significantly disrupted egg supplies. According to the U.S. Bureau of Labor Statistics and USDA data, the price of eggs in August 2024 increased by 57% year-over-year, while powdered whole egg prices rose by 15%. As a result, food manufacturers are actively seeking egg substitutes to mitigate supply shortages and price volatility. Burcon's canola protein isolate, with over 90% protein purity and exceptional functionality, is a suitable egg replacement in bakery applications. In a side-by-side study, Burcon's canola protein has demonstrated the ability to replace up to 100% of powdered and shelled eggs, delivering cost-in-use savings of 20 - 30%. This great-tasting canola protein not only provides superior functionality and price stability but also offers a vegan-friendly option for consumers. Announcement • Sep 20
Burcon NutraScience Corporation Announces Board Changes Burcon NutraScience Corporation at its annual general and special meeting of shareholders held on September 18, 2024, announced that, Mr. James Pekar was elected as a director of the Company. Mr. Pekar has over 30 years' of experience in the dairy and food industry. Born and raised in Wisconsin, United States, Mr. Pekar received a full athletic scholarship to attend the University of Iowa to play football. His football career spanned from 1978 to 1987, from playing with the Iowa Hawkeyes to the LA Express and San Antonio Gunslingers, two USFL football teams. In 1994, Mr. Pekar started a dairy based enzyme-modified reaction company, named First Choice Ingredients, which specialized in reaction, fermentation and distillation technologies. Started in the basement of his first home, Mr. Pekar grew First Choice from one employee to over 150 employees and three plants (which included 150,000+ square feet of office and manufacturing space) and operated the business successfully for 27 years. Dr. Lorne Tyrrell retired from the board of directors and did not stand for re-election at the Meeting this year. Announcement • Jul 09
Burcon NutraScience Corporation, Annual General Meeting, Sep 18, 2024 Burcon NutraScience Corporation, Annual General Meeting, Sep 18, 2024. Announcement • Jun 14
Burcon NutraScience Corporation to Report Fiscal Year 2024 Results on Jun 26, 2024 Burcon NutraScience Corporation announced that they will report fiscal year 2024 results on Jun 26, 2024 Announcement • Mar 13
Burcon NutraScience Corporation announced that it has received CAD 4.36416 million in funding Burcon NutraScience Corporation announced it has completed an over-subscribed non-brokered private placement of 20,298,418 units at an issue price of CAD 0.215 per Unit for gross proceeds of CAD 4,364,159.87 on March 12, 2024. The transaction included participation from company directors, management, long-term shareholders, and new investors in support of it's long-term vision. Each unit consists of one common share in the capital of the Company and one-half of one Common Share purchase warrant of the Company. Each Warrant entitles the holder thereof to purchase one Common Share at a price of CAD 0.27 per Warrant Share for a period of 24 months after the closing date of the Offering. All securities issued in connection with the Offering are subject to a statutory hold period in Canada expiring four months and one day from the closing of the private placement. n connection with the Offering, the Company paid eligible finders an aggregate cash finder fee of CAD 5,160, representing a cash commission of 4% of the gross proceeds of subscribers introduced to the Company by such finders. Announcement • Feb 01
Burcon NutraScience Corporation to Report Q3, 2024 Results on Feb 14, 2024 Burcon NutraScience Corporation announced that they will report Q3, 2024 results on Feb 14, 2024 Announcement • Nov 02
Burcon NutraScience Corporation to Report Q2, 2024 Results on Nov 14, 2023 Burcon NutraScience Corporation announced that they will report Q2, 2024 results on Nov 14, 2023 Announcement • Sep 21
Burcon NutraScience Corporation Announces Board Changes Burcon NutraScience Corporation announced that, Mr. John A. Vassallo was elected as a director of the Company. Mr. Vassallo has over 30 years' experience in asset acquisition, development and management across several industries in multiple states. As Founder and CEO of Mos RE, LLC, Mr. Vassallo focuses on real estate development, land entitlements, redevelopment and strategic reuse of underutilized buildings by utilizing multi-source financing packages, including historic tax credits, tax incremental financing and state development programs. Mr. Vassallo headed multiple capital raises for a variety of developments and acquisitions. Mr. Vassallo also has experience in purchasing distressed debt for profitable returns. As Founder and CEO of Global Restaurant Systems, LLC, Mr. Vassallo established a multi-faceted management and consulting company providing inclusive restaurant development and operating services including accounting, human resources, real estate analysis and acquisition, legal, marketing, IT and administrative support to its clients. Mr. Vassallo currently holds approximately 3.8% of Burcon's issued and outstanding common shares. Mr. J. Douglas Gilpin did not stand for re-election at the Meeting this year. Announcement • Jul 08
Burcon NutraScience Corporation, Annual General Meeting, Sep 20, 2023 Burcon NutraScience Corporation, Annual General Meeting, Sep 20, 2023. Announcement • Jun 13
Burcon NutraScience Corporation to Report Fiscal Year 2023 Results on Jun 22, 2023 Burcon NutraScience Corporation announced that they will report fiscal year 2023 results on Jun 22, 2023 Announcement • May 18
Burcon NutraScience Corporation announced that it has received CAD 3.41342 million in funding On may 16, 2023, the Company has issued a further 3,884,603 Units at a price of CAD 0.265 per Unit for gross proceeds of CAD 1,029,420 for its third and final tranche. Together with the first and second tranche of the Offering, the Company issued a total of 12,880,829 Units for gross proceeds of CAD 3,413,420. In connection with the Offering, the Company paid eligible finders an aggregate cash finder fee of CAD 9,440. Announcement • May 11
Burcon Announces Sunflower Protein Process Commercially Ready Burcon NutraScience Corporation announce that it has successfully completed end-to-end validation trials of its novel sunflower protein process using commercial-scale equipment at Burcon's Winnipeg Technical Centre. Burcon has validated that its innovative sunflower protein process is robust and ready for commercial scale-up. Burcon's sunflower protein isolates are greater than 90% pure protein, have a neutral flavor profile and are white in color allowing incorporation into many plant-based foods. Initial feedback on Burcon's novel sunflower protein isolate has been overwhelmingly positive. Process validation is a key milestone towards successful commercialization of Burcon's technologies. As part of company's Burcon 2.0 strategy to get closer to customers and end markets, and to have greater control over the manufacture of Burcon's proteins, the Company is evaluating and pursuing multiple routes to market. Discussions with potential partners to bring this technology to market are progressing well, with interested parties wanting to move forward on this project. Concurrent to partnership discussions, Burcon is exploring additional routes to market with the goal of reducing the time required to achieve commercial production and sales. Announcement • May 10
Burcon NutraScience Corporation announced that it expects to receive CAD 3.376451 million in funding Burcon NutraScience Corporation announced a non-brokered private placement of 12,741,321 units at an issue price of CAD 0.265 per unit for the gross proceeds of CAD 3,376,450 on May 8, 2023. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder thereof to purchase one common share at a price of CAD 0.35 per warrant share for a period of 36 months after the closing date of the transaction. All securities issued in connection with the transaction are subject to a statutory hold period in Canada expiring four months and one day from the closing of the transaction. The Transaction is expected to close in two tranches, the first on May 8, 2023 and the second tranche on or before May 11, 2023.
On the same date the company received 5,784,802 units at a price of CAD 0.265 per unit for aggregate gross proceeds of approximately CAD 1,530,000. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder thereof to purchase one common share at a price of $0.35 per warrant share for a period of 36 months after the closing date of the offering. All securities issued in connection with the offering are subject to a statutory hold period in Canada expiring four months and one day from the closing of the private placement. The second tranche is expected on or before May 11, 2023. Announcement • Feb 02
Burcon NutraScience Corporation to Report Q3, 2023 Results on Feb 14, 2023 Burcon NutraScience Corporation announced that they will report Q3, 2023 results on Feb 14, 2023 Reported Earnings • Aug 16
First quarter 2023 earnings released: CA$0.04 loss per share (vs CA$0.029 loss in 1Q 2022) First quarter 2023 results: CA$0.04 loss per share (down from CA$0.029 loss in 1Q 2022). Net loss: CA$4.00m (loss widened 26% from 1Q 2022). Over the next year, revenue is forecast to grow 493%, compared to a 12% growth forecast for the Chemicals industry in the US. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings. Reported Earnings • Jun 28
Full year 2022 earnings released Full year 2022 results: Net loss: CA$10.3m (loss widened CA$9.64m from FY 2021). Over the next year, revenue is forecast to grow 1,092%, compared to a 14% growth forecast for the industry in the US. Buying Opportunity • Apr 11
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 37%. The fair value is estimated to be US$1.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 89% over the last 3 years. Meanwhile, the company became loss making. For the next 3 years, revenue is forecast to grow by 47% per annum. Earnings is also forecast to grow by 61% per annum over the same time period. Reported Earnings • Nov 17
Second quarter 2022 earnings released: CA$0.01 loss per share (vs CA$0.044 profit in 2Q 2021) Second quarter 2022 results: Net loss: CA$1.35m (down 131% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has increased by 93% per year, which means it is tracking significantly ahead of earnings growth. Executive Departure • Sep 17
Director Chi Ng has left the company On the 16th of September, Chi Ng's tenure as Director ended after 2.2 years in the role. We don't have any record of a personal shareholding under Chi's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 12.00 years. Executive Departure • Sep 17
Independent Director David Ju has left the company On the 16th of September, David Ju's tenure as Independent Director ended after 3.7 years in the role. We don't have any record of a personal shareholding under David's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 12.00 years. Recent Insider Transactions • Sep 12
Director recently sold US$69k worth of stock On the 8th of September, Chi Ng sold around 30k shares on-market at roughly US$2.30 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$133k more than they bought in the last 12 months. Reported Earnings • Aug 21
First quarter 2022 earnings released: CA$0.029 loss per share (vs CA$0.014 loss in 1Q 2021) First quarter 2022 results: Net loss: CA$3.18m (loss widened 127% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has increased by 96% per year, which means it is tracking significantly ahead of earnings growth. Breakeven Date Change • Jul 02
Forecast breakeven pushed back to 2023 The analyst covering Burcon NutraScience previously expected the company to break even in 2022. New forecast suggests the company will make a profit of CA$577.0k in 2023. Average annual earnings growth of 75% is required to achieve expected profit on schedule. Reported Earnings • Jul 01
Full year 2021 earnings released Full year 2021 results: Net loss: CA$617.5k (loss narrowed 87% from FY 2020). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has increased by 97% per year, which means it is tracking significantly ahead of earnings growth. 
